GRIPE
发表于 2025-3-26 21:46:35
http://reply.papertrans.cn/27/2643/264237/264237_31.png
VOK
发表于 2025-3-27 02:40:39
http://reply.papertrans.cn/27/2643/264237/264237_32.png
Canary
发表于 2025-3-27 08:46:12
http://reply.papertrans.cn/27/2643/264237/264237_33.png
大洪水
发表于 2025-3-27 09:49:40
Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in HealP process for priority ranking medical devices and how it differs from a pharmaceutical review, and how HTERP comes to developing their recommendations. We conclude with providing opportunities for improvement within CADTH’s device recommendations and discuss the future challenges of pushing disinve
Axillary
发表于 2025-3-27 17:02:00
Challenges and Opportunities in the Dissemination of Comparative Effectiveness Research Information ed FDAMA-114 to broaden the meaning of HCEI and loosened restrictions on the dissemination of HCEI as well as draft guidance issued by the FDA. Previously, restrictions on manufacturers’ ability to provide HCEI and other scientific information contributed to an asymmetry of information between manuf
抛物线
发表于 2025-3-27 20:15:52
Legal Considerations in a World of Comparative Effectiveness Researche the expertise of the spokesperson may matter). In addition, they talk about managing company risk in an environment where some communications may be seen as off label and others may be seen as false or misleading. Finally, they talk about specific examples in which CER has been used effectively in
outrage
发表于 2025-3-27 22:03:43
http://reply.papertrans.cn/27/2643/264237/264237_37.png
intricacy
发表于 2025-3-28 02:32:36
Decision Making in a World of Comparative Effectiveness Research978-981-10-3262-2
Accord
发表于 2025-3-28 09:23:07
http://reply.papertrans.cn/27/2643/264237/264237_39.png
遗传学
发表于 2025-3-28 11:20:53
http://reply.papertrans.cn/27/2643/264237/264237_40.png